quinazolines has been researched along with Sensitivity and Specificity in 126 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (7.94) | 18.2507 |
| 2000's | 69 (54.76) | 29.6817 |
| 2010's | 45 (35.71) | 24.3611 |
| 2020's | 2 (1.59) | 2.80 |
| Authors | Studies |
|---|---|
| Dittakavi, S; Kumar, R; Mullangi, R; Siddesh, A; Sriram, D; Trivedi, RK; Zainuddin, M; Zakkula, A | 1 |
| Beijnen, JH; Rood, JJM; Somovilla, VJ; Sparidans, RW; Toraño, JS | 1 |
| Haglund, C; Hermunen, K; Lantto, E; Österlund, P; Poussa, T | 1 |
| Alexandre, J; Allard, M; Arrondeau, J; Bellesoeur, A; Blanchet, B; Boudou-Rouquette, P; Chapron, J; Giraud, F; Goldwasser, F; Labat, L; Reis, R; Thomas-Schoemann, A; Vidal, M | 1 |
| Huang, MQ; Kocan, GP; Li, F; Pai, S | 1 |
| Dittakavi, S; Mullangi, R | 1 |
| Idippily, N; Li, Y; Petty, A; Su, B; Wang, B; Zhong, B | 1 |
| Blanchet, B; Boudou-Rouquette, P; Dupin, N; Goldwasser, F; Mortier, L; Sakji, L; Thomas-Schoemann, A; Vidal, M; Zhen, Y | 1 |
| Fujita, Y; Horiike, A; Irwin, DL; Kaburaki, K; Kudo, K; Nishio, K; Nishio, M; Ohyanagi, F; Saito, R; Sakai, K; Sakatani, T; Tanimoto, A; Yanagitani, N | 1 |
| Andrews, GA; Byers, LA; Fooshee, DR; Frederick, MJ; Galer, C; Hah, JH; Heymach, J; Jasser, SA; Kim, E; Milas, ZL; Myers, JN; Papadimitrakopoulou, V; Pickering, CR; Sano, D; William, WN; Zhao, M | 1 |
| Das, S; Mandal, M; Mitra, A; Pradhan, R; Rajput, S | 1 |
| Ma, J; Wang, X; Wen, C; Xiang, Z; Zhang, Q | 1 |
| Ito, H; Kobayashi, H; Miura, H; Miura, M; Narita, C; Niioka, T; Sato, K | 1 |
| Chiara, MD; de Santa-María, IS; Merlo, A; Secades, P; Suarez, C | 1 |
| Hua, Y; Liu, J; Liu, Z; Sun, Y; Wang, C; Wang, Z; Zhang, N | 1 |
| Alejandre, MJ; Aránega, A; Caba, O; Delgado, JR; Iglesias, J; Irigoyen, A; Linares, A; Martin, M; Ortuño, FM; Palomino, RJ; Perales, S; Prados, JC; Rojas, I; Torres, C | 1 |
| Niessen, HG; Poot, AJ; Schuit, RC; Slobbe, P; Smit, EF; Solca, F; Stehle, G; Stigter-van Walsum, M; van Dongen, GA; Windhorst, AD | 1 |
| Brandes, AA; Buttitta, F; Centi, I; Chella, A; Crinò, L; Cuccurullo, F; De Pas, T; Del Grammastro, M; Felicioni, L; Filice, G; Malatesta, S; Marchetti, A; Santoro, A; Venturino, P | 1 |
| Cho, HJ; Chung, DH; Jeon, YK; Keam, B; Kim, DW; Kim, TM; Koh, J; Lee, DS; Lee, SH; Won, JK | 1 |
| Chuttani, K; Dhawan, D; Ghai, A; Kumar, P; Mishra, AK; Mittal, BR; Singh, B | 1 |
| Davisson, RL; Eguchi, S; Elliott, KJ; Forrester, SJ; Fukuda, Y; Kawai, T; Obama, T; Park, JY; Takayanagi, T; Tilley, DG; Tsuji, T | 1 |
| Fang, L; Li, F; Lin, N; Song, Y; Weng, X; Xu, Y | 1 |
| Geng, D; Sun, D; Zhang, L; Zhang, W | 1 |
| Collins, DJ; Darcy, J; Desouza, N; Leach, MO; Messiou, C; Orton, MR; Rata, M; Tunariu, N; Young, H | 1 |
| Han, SY; He, XR; Jiang, ST; Li, PP; Xu, GB; Zhao, C; Zheng, N | 1 |
| Syed, YY | 1 |
| Arimoto, T; Honda, Y; Kadomatsu, K; Kadowaki, S; Kinoshita, D; Kishida, S; Kubota, I; Miyamoto, T; Narumi, T; Netsu, S; Nishiyama, S; Shishido, T; Takahashi, H; Takahashi, T; Takeishi, Y; Watanabe, T | 1 |
| Dietel, M; Eberhardt, W; Griesinger, F; Radke, S; Schirmacher, P; Schuette, W; Thomas, M; Zirrgiebel, U | 1 |
| Azas, N; Desroches, J; El-Kashef, H; Gellis, A; Hutter, S; Kieffer, C; Primas, N; Rathelot, P; Vanelle, P; Verhaeghe, P | 1 |
| Hsiue, EH; Lee, JH; Lin, CC; Yang, JC | 1 |
| Song, Z; Wang, W; Zhang, Y | 1 |
| Cai, Z; Gong, X; Li, Z; Zhao, Y; Zhou, C; Zhou, X | 1 |
| Bertran-Alamillo, J; Botia, M; Carrasco, E; Castellà, E; Costa, C; Llatjós, M; Mate, JL; Mayo, C; Molina-Vila, MA; Moran, T; Pérez-Cano, M; Pradas, A; Queralt, C; Reguart, N; Rosell, R; Taron, M; Tomàs, M | 1 |
| Arabshahi, A; Barnes, S; Carroll, SL; Moore, R; Prasain, JK | 1 |
| Jangid, AG; Mistri, HN; Pudage, A; Rathod, DM; Shrivastav, PS | 1 |
| Hay, JW; Le, QA | 1 |
| Bunn, PA; Franklin, WA; Hirsch, FR; Kosaka, T; Mitsudomi, T; Nakajima, E; Skokan, M; Varella-Garcia, M; Xavier, AC; Yatabe, Y; Zeng, C | 1 |
| Ferancová, A; Galandová, J; Labuda, J; Ovádeková, R | 1 |
| Doral Stefani, S; Giorgio Saggia, M; Vicino dos Santos, EA | 1 |
| Li, S; Liu, G; Lu, Y; Wang, Y; Yang, D; Yu, C | 1 |
| Ganesh, M; Gangully, S; Kamalakannan, K; Rathinavel, G; Sivakumar, T; Tivari, R; Uppatyay, S | 1 |
| Date, H; Hotta, K; Jida, M; Kiura, K; Kubo, T; Matsuo, K; Mitsudomi, T; Miyoshi, S; Ohe, Y; Oto, T; Sano, Y; Takano, T; Toyooka, S; Tsukuda, K; Yamamoto, H; Yamane, M; Yatabe, Y | 1 |
| Chae, S; Cho, JG; Hwang, SJ; Jung, HH; Lee, HM; Woo, JS | 1 |
| Al-Sarraj, S; Bax, DA; Ellison, DW; Gaspar, N; Hargrave, D; Jones, C; Little, SE; Marshall, L; Pearson, AD; Perryman, L; Regairaz, M; Reis, RM; Reis-Filho, JS; Sharp, SY; Stávale, JN; Vassal, G; Viana-Pereira, M; Vuononvirta, R; Workman, P | 1 |
| Hu, P; Jiang, J; Liu, D; Tan, F; Wang, Y | 1 |
| Clynes, M; McMahon, G; O'Connor, R; Roche, S | 1 |
| Cheon, S; Cho, H; Espina, V; Havaleshko, DM; Lee, JK; Liotta, LA; Owens, CR; Petricoin, EF; Smith, SC; Theodorescu, D; Wulfkuhle, JD | 1 |
| Wachsberger, P; Yan, K; Yu, Y | 1 |
| Guo, P; Kris, MG; Ladanyi, M; Moskowitz, CS; Oxnard, GR; Pao, W; Rizvi, NA; Rusch, VM; Schwartz, LH; Zhao, B | 1 |
| de Ruysscher, D; Dingemans, AM; Lind, JS; Meijerink, MR; Ollers, MC; Postmus, PE; Smit, EF; van Kuijk, C | 1 |
| Andrews, GA; Fooshee, DR; Frederick, MJ; Galer, C; Milas, ZL; Morrow, PK; Myers, JN; Sano, D; Zhao, M | 1 |
| Allal, BC; Brillouet, S; Canal, P; Caselles, O; Courbon, F; Delord, JP; Filleron, T; Rochaix, P; Thomas, F; Vergez, S | 1 |
| Abe, H; Aikawa, E; Akiba, J; Azuma, K; Kage, M; Kawahara, A; Nakashima, K; Sumi, A; Taira, T; Takamori, S; Yamaguchi, T | 1 |
| Borget, I; Cadranel, J; Chouaid, C; Coudert, B; Daniel, C; Dansin, E; Friard, S; Madelaine, J; Madroszyk, A; Morin, F; Pignon, JP; Quoix, E; Westeel, V | 1 |
| Bai, F; Broniscer, A; Johnson, J; Stewart, CF; Wang, F; Yang, L | 1 |
| Abe, T; Hayashi, S; Hirai, M; Hosomi, T; Iwanaga, K; Kimura, S; Komiya, K; Nakamura, T; Sato, A; Sueoka, E; Sueoka-Aragane, N; Ureshino, N | 1 |
| Elmquist, WF; Oberoi, RK; Wang, T | 1 |
| Beijnen, JH; Durmus, S; Schellens, JH; Schinkel, AH; Sparidans, RW; Xu, N | 1 |
| Chudasama, J; Guttikar, S; Guy, B; Jakab, A; Kovarik, JM; Kretz, O; Picard, F; Raccuglia, M; Singhal, P; Winter, S | 1 |
| Bokacheva, L; Carlin, S; Halliday, J; Kotedia, K; Koutcher, JA; Le, CH; Reese, M; Ricketts, SA | 1 |
| Ang, JE; Brunetto, A; Castellano, I; Collins, DJ; deBono, JS; deSouza, NM; Ghiorghiu, D; Kaye, SB; Leach, MO; Mann, H; Marley, S; Mears, D; Messiou, C; Morgan, VA; Orton, M; Papadatos-Pastos, D; Tessier, J; Tunariu, N; Young, H | 1 |
| Chang, PM; Chen, CC; Chen, KY; Chiou, JF; Ho, CC; Hsiao, M; Huang, CY; Kuo, YL; Lai, JM; Lee, PY; Liu, YW; Lu, PJ; Wang, LS; Wu, AT; Wu, CH; Yang, CN; Yang, PC; Yang, SC; Yeh, CT; Yen, CC | 1 |
| Beijnen, JH; Burgers, JA; Huitema, AD; Lankheet, NA; Rosing, H; Schaake, EE; Schellens, JH | 1 |
| Mukkanti, K; Thappali, SR; Vakkalanka, SK; Varanasi, KV; Veeraraghavan, S | 1 |
| Hundt, AF; Hundt, HK; Sutherland, FC; Swart, KJ; van Essen, GH; Wiesner, JL | 1 |
| Bartolini, S; Calandri, C; Cancellieri, A; Cappuzzo, F; Ceresoli, G; Crino, L; de Rosa, M; Gregorc, V; Lombardo, L; Magrini, E; Paties, CT; Rossi, E; Villa, E | 1 |
| Baker, SD; He, P; Hidalgo, M; Rudek, MA; Zhao, M | 1 |
| Capilla, J; Guarro, J; Javier Pastor, F; Ortoneda, M; Pujol, I | 1 |
| Baselga, J | 1 |
| Belloc, J; Parella, T; Sánchez-Ferrando, F | 1 |
| Chen, EX; Moore, MJ; Siu, LL; Zhang, W | 1 |
| de Arruda Rolim Filho, L; Franchini, KG; Marin, RM; Rittner, R; Rocco, SA; Velho, JA; Vercesi, AE | 1 |
| Attard, G; De Bono, J; Kaye, S; Vidal, L | 1 |
| Carlomagno, F; Santoro, M | 1 |
| Belani, CP; Cella, D; Herbst, RS; Heyes, A; Kay, AC; Kris, MG; Lynch, TJ; Natale, RB; Ochs, JS; Prager, D; Schiller, JH; Wolf, MK | 1 |
| Bang, YJ; Choi, IS; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Jeong, S; Kim, DW; Kim, J; Kim, JH; Kim, NK; Kim, TY; Kim, YT; Lee, JS; Oh, DY | 1 |
| Endoh, H; Hatooka, S; Hida, T; Horio, Y; Kosaka, T; Mitsudomi, T; Mori, S; Shinoda, M; Takahashi, T; Yatabe, Y | 1 |
| Baker, SD; Hartke, C; He, P; Hidalgo, M; Jimeno, A; Li, J; Zabelina, Y; Zhao, M | 1 |
| Bradshaw, EL; Gustafson, DL; Long, ME; Zirrolli, JA | 1 |
| Gonthier, R; Neirinck, L; Zhu, Z | 1 |
| De Boeck, G; de Bruijn, EA; Esmans, E; Guetens, G; Lemière, F; Prenen, H; Schöffski, P; Van Dongen, W; van Oosterom, AT | 1 |
| Fukuyama, S; Hagiwara, K; Kanazawa, M; Kato, M; Kobayashi, K; Miyazawa, H; Nagai, Y; Tanaka, T; Udagawa, K; Yokote, A | 1 |
| Hong, SJ; Jae, YW; Kim, SI; Kwon, SM; Oh, HY | 1 |
| Fukui, T; Hasegawa, Y; Imaizumi, K; Kondo, M; Kume, H; Nagasaka, T; Sekido, Y; Shimokata, K; Yokoi, K; Yokoyama, T; Yoshioka, H | 1 |
| Endo, K; Fujii, Y; Fukai, I; Haneda, H; Iuchi, K; Kawahara, M; Kobayashi, Y; Konishi, A; Kuwabara, Y; Matsumura, A; Mizuno, K; Okumura, M; Sasaki, H; Sugiura, H; Suzuki, E; Takada, M; Tanaka, H; Yano, M | 1 |
| Fujito, H; Mori, M; Saita, T | 1 |
| Donson, AM; Foreman, NK; Gore, L; Heideman, R; Straessle, J; Wells, D | 1 |
| Frantz, S | 1 |
| Jacobson, JW; Lively, TG; Taube, SE | 1 |
| Borras, AM; Distel, RJ; Halmos, B; Jänne, PA; Johnson, BE; Joshi, VA; Kuang, Y; Lee, JC; Lindeman, N; Liyanage, H; Maher, EA; Meyerson, M; Rogers, AM | 1 |
| Kris, MG; Ladanyi, M; Li, AR; Miller, VA; Pao, W; Pham, D; Riely, GJ; Rizvi, N; Venkatraman, ES; Zakowski, MF | 1 |
| Brown, KA; Emlet, DR; Pollice, AA; Schwartz, R; Shackney, SE; Smith, CA | 1 |
| Holloway, B; Kasahara, K; Kawaishi, M; Kimura, H; Kunitoh, H; Nishio, K; Tamura, T | 1 |
| Elenius, K; Erjala, K; Grenman, R; Junttila, TT; Kulmala, J; Mali, P; Pulkkinen, J; Savisalo, M; Sundvall, M; Zhang, N | 1 |
| Hida, T; Horio, Y; Kosaka, T; Mitsudomi, T; Takahashi, T; Yatabe, Y | 1 |
| Maekawa, M; Okusaka, T; Yamada, T | 1 |
| Shiratori, M; Takahashi, H | 1 |
| Bozec, A; Fischel, JL; Formento, P; Gugenheim, J; Hofman, P; Lassalle, S; Milano, G | 1 |
| But, PP; Cai, M; Ding, LS; Jiang, RW; Li, SH; Liu, X; Shaw, PC; Xu, HX; Zhou, Y | 1 |
| Bodenstein, C; Czernin, J; Dubinett, S; Dumont, RA; Herschman, H; Phelps, ME; Seimbille, Y; Su, H; Weber, W | 1 |
| Fujiwara, Y; Kasahara, K; Kimura, H; Kunitoh, H; Nishio, K; Sone, T; Tamura, T | 1 |
| Ahmad, B; Anuar, D; Chin, TM; Goh, BC; Iacopetta, B; Kawakami, K; Lee, SC; Li, WQ; Salto-Tellez, M; Segal, A; Soo, R; Soong, R | 1 |
| Abdel-Aaty Shehata, M; El-Weshahy, SA; Salah Fayed, A; Yehia Hassan, N | 1 |
| Griffiths, TR; Kriajevska, M; McHugh, LA; Mellon, JK | 1 |
| Aoe, M; Date, H; Kiura, K; Kosaka, T; Mitsudomi, T; Ogino, A; Ouchida, M; Shigematsu, H; Soh, J; Takata, M; Toyooka, S; Uchida, A | 1 |
| Eichler, GS; Kane, D; Reimers, M; Weinstein, JN | 1 |
| Araya, T; Fujimura, M; Kasahara, K; Kimura, H; Koizumi, F; Miyamoto, K; Nakao, S; Nishio, K; Sone, T; Suminoe, M; Tamori, S | 1 |
| Balak, M; Chmielecki, J; Gong, Y; Jiang, X; Pao, W; Politi, K; Somwar, R | 1 |
| Gupta, B; Gupta, VK; Singh, AK | 1 |
| Ben Ahmed, S; Blackwell, K; Boussen, H; Citrin, DL; DeSilvio, ML; Harris, J; Johnston, S; Kaufman, B; Lombardi, DP; LoRusso, P; Salazar, V; Spector, NL; Trudeau, M; Westlund, RE; Zaks, TZ | 1 |
| Hagiwara, K; Hirama, T; Ikebuchi, K; Kanazawa, M; Kobayashi, K; Koyama, N; Matsuoka, M; Miyazawa, H; Murayama, Y; Nagai, Y; Nagata, M; Nukiwa, T; Sutani, A; Takenoshita, S; Tanaka, T; Udagawa, K; Zhang, J | 1 |
| Alvarez, R; Conti, M; Eglen, RM; Sette, C; Shelton, ER; Wilhelm, R; Yang, D | 1 |
| Brasso, K; Flyger, H; Hald, T; Hansen, BJ; Meyhoff, HH; Mortensen, S; Nordling, J; Schou, J; Thorup Andersen, J; Walter, S | 1 |
| Grover, PK; Gupta, RC; Paliwal, JK; Singh, SK | 1 |
| Horie, T; Takase, Y; Tokumura, T | 1 |
| Backman-Gullers, B; Kågedal, B; Lundquist, P; Nilsson, L; Rosling, H | 1 |
| Comet, D; Grange, JC; Lukacs, B; Thibault, P | 1 |
| Bechard, B; Chen, CL; Chen, H; Liu, XP; Malaviya, R; Mitcheltree, G; Navara, C; Uckun, FM | 1 |
| Chen, CL; Chen, H; Liu, XP; Malaviya, R; Uckun, FM | 1 |
| Cox, WG; Singer, VL | 1 |
| Adamson, PC; Balis, FM; Godwin, KS; McCully, C; Widemann, BC | 1 |
| Jackman, AL; Lynn, S; Mitchell, F | 1 |
| Gras, S; Hill, BT; Perrin, D; van Hille, B | 1 |
| Burgess, AW; Ellis, AG; Levitzki, A; Nice, EC; Webster, LK; Weinstock, J | 1 |
| Curtin, NJ; Errington, J; Lu, X; Lunec, J; Newell, DR | 1 |
| Ashton, SE; Barker, AJ; Barlow, JJ; Curry, BJ; Gibson, KH; Godfrey, AA; Grundy, W; Healy, MP; Henthorn, L; Richards, L; Scarlett, L; Woodburn, JR | 1 |
4 review(s) available for quinazolines and Sensitivity and Specificity
| Article | Year |
|---|---|
Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Quinazolines; Reagent Kits, Diagnostic; Real-Time Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Analysis, DNA | 2016 |
Reversing resistance to targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Imatinib Mesylate; Male; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Risk Assessment; Sensitivity and Specificity; Trastuzumab | 2004 |
Cancer diagnostics: decision criteria for marker utilization in the clinic.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow Examination; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Genetic Testing; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Neoplasm, Residual; Neoplasms; Neoplastic Cells, Circulating; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Technology Assessment, Biomedical; Trastuzumab | 2005 |
[Diffuse lung diseases and biological markers in serum].
Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Biomarkers; Collagen Diseases; Gefitinib; Humans; Lung Diseases, Interstitial; Mucin-1; Mucins; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Protein D; Quinazolines; Radiation Pneumonitis; Reagent Kits, Diagnostic; Respiratory Distress Syndrome; Sensitivity and Specificity | 2006 |
16 trial(s) available for quinazolines and Sensitivity and Specificity
| Article | Year |
|---|---|
Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Quinazolines; ROC Curve; Sensitivity and Specificity; Thiophenes; Tomography, X-Ray Computed | 2018 |
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.
Topics: Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Expression; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity | 2014 |
Assessment of repeatability and treatment response in early phase clinical trials using DCE-MRI: comparison of parametric analysis using MR- and CT-derived arterial input functions.
Topics: Abdominal Neoplasms; Adult; Aged; Algorithms; Antineoplastic Agents; Aorta; Computer Simulation; Contrast Media; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2016 |
[Exon-dependent Subgroup-analysis of the Non-interventional REASON-Study: PFS and OS in EGFR-mutated NSCLC Patients Treated with Gefitinib or Chemotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Genetic Markers; Genetic Predisposition to Disease; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Pharmacogenomic Testing; Point Mutation; Prevalence; Quinazolines; Radiation Injuries; Reproducibility of Results; Risk Factors; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2016 |
A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Gefitinib; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Pilot Projects; Prognosis; Quinazolines; Sensitivity and Specificity; Tomography, X-Ray Computed; Tumor Burden | 2010 |
Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Contrast Media; Erlotinib Hydrochloride; Female; Humans; Iohexol; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Radiographic Image Enhancement; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI.
Topics: Animals; Antineoplastic Agents; Contrast Media; Fluorodeoxyglucose F18; Gadolinium DTPA; HT29 Cells; Humans; Neoplasms, Experimental; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Rats; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Contrast Media; Dose-Response Relationship, Drug; Female; Gadolinium DTPA; Humans; Iohexol; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Preoperative Care; Probability; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2003 |
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Double-Blind Method; Endpoint Determination; Female; Gefitinib; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Sensitivity and Specificity; Survival Analysis | 2005 |
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Quinazolines; Sensitivity and Specificity; Sequence Analysis, DNA; Signal Transduction; Survival Analysis | 2005 |
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
Topics: Adult; Aged; Amino Acid Sequence; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Neoplasm Recurrence, Local; Point Mutation; Predictive Value of Tests; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; RNA; Sensitivity and Specificity; Sex Factors; Survival Analysis | 2005 |
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2006 |
Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Point Mutation; Predictive Value of Tests; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Deletion; Survival Rate; Treatment Outcome | 2006 |
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Female; Humans; Immunoenzyme Techniques; Inflammation; Lapatinib; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Sensitivity and Specificity; Skin Neoplasms | 2008 |
Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Surveys and Questionnaires; Urination Disorders | 1995 |
106 other study(ies) available for quinazolines and Sensitivity and Specificity
| Article | Year |
|---|---|
Validated HPLC-UV method for simultaneous quantification of phosphatidylinositol 3-kinase inhibitors, copanlisib, duvelisib and idelalisib, in rat plasma: Application to a pharmacokinetic study in rats.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Isoquinolines; Linear Models; Liquid-Liquid Extraction; Male; Phosphoinositide-3 Kinase Inhibitors; Purines; Pyrimidines; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity | 2021 |
Bioanalysis of erlotinib, its O-demethylated metabolites OSI-413 and OSI-420, and other metabolites by liquid chromatography-tandem mass spectrometry with additional ion mobility identification.
Topics: Chromatography, Liquid; Erlotinib Hydrochloride; Isomerism; Linear Models; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2021 |
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung canc
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Crizotinib; Drug Monitoring; Drug Stability; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Limit of Detection; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
A sensitive LC-MS-MS assay for the determination of lapatinib in human plasma in subjects with end-stage renal disease receiving hemodialysis.
Topics: Chromatography, Liquid; Drug Stability; Humans; Kidney Failure, Chronic; Lapatinib; Linear Models; Neoplasms; Quinazolines; Renal Dialysis; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
LC-ESI-MS/MS determination of copanlisib, a novel PI3K inhibitor, in mouse plasma and its application to a pharmacokinetic study in mice.
Topics: Animals; Chromatography, Liquid; Linear Models; Male; Mice; Mice, Inbred BALB C; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2019 |
A quantitative LC-MS/MS method for determination of a small molecule agonist of EphA2 in mouse plasma and brain tissue.
Topics: Animals; Brain Chemistry; Chromatography, Liquid; Female; Linear Models; Mice; Piperazines; Quinazolines; Receptor, EphA2; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2019 |
An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Drug Monitoring; Erlotinib Hydrochloride; Humans; Indoles; Liquid-Liquid Extraction; Melanoma; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides; Vemurafenib | 2013 |
Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Adult; Aged; Alleles; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity | 2013 |
HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
Topics: Animals; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Mice; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Sensitivity and Specificity; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transfection | 2014 |
Frequency dependent impedimetric cytotoxic evaluation of anticancer drug on breast cancer cell.
Topics: Antineoplastic Agents; Apoptosis; Biological Assay; Biosensing Techniques; Breast Neoplasms; Cell Proliferation; Dielectric Spectroscopy; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Equipment Design; Equipment Failure Analysis; Female; Humans; MCF-7 Cells; Piperidines; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2014 |
Determination of CUDC-101 in rat plasma by liquid chromatography mass spectrometry and its application to a pharmacokinetic study.
Topics: Administration, Intravenous; Animals; Calibration; Chromatography, Liquid; Histone Deacetylase Inhibitors; Hydroxamic Acids; Male; Quinazolines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2014 |
A limited sampling strategy for estimation of the area under the plasma concentration-time curve of gefitinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Diarrhea; Drug Monitoring; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; ROC Curve; Sensitivity and Specificity; Specimen Handling; Time Factors | 2014 |
In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth fact
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; In Vitro Techniques; Membrane Proteins; Polymerase Chain Reaction; Predictive Value of Tests; Proto-Oncogene Proteins; Quinazolines; Sensitivity and Specificity; Signal Transduction; Vascular Endothelial Growth Factor A | 2015 |
Distribution study of tryptanthrin in rat tissues by HPLC and its relationship with meridian tropism of indigo naturalis in traditional Chinese medicine.
Topics: Animals; Chromatography, High Pressure Liquid; Drugs, Chinese Herbal; Linear Models; Meridians; Quinazolines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution | 2014 |
Serum cytokine profile in patients with pancreatic cancer.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Comorbidity; Cytokines; Deoxycytidine; Diabetes Mellitus, Type 2; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Predictive Value of Tests; Quinazolines; ROC Curve; Sensitivity and Specificity; Smoking; Tumor Microenvironment | 2014 |
Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors.
Topics: Afatinib; Animals; Cell Line, Tumor; ErbB Receptors; Fluorine Radioisotopes; Isotope Labeling; Metabolic Clearance Rate; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Organ Specificity; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution | 2014 |
Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; DNA Mutational Analysis; Female; Gefitinib; Genes, erbB-1; High-Throughput Nucleotide Sequencing; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor Protein-Tyrosine Kinases; Sensitivity and Specificity; Sulfones; Translocation, Genetic | 2015 |
Preclinical evaluation of (99m)Tc labeled gefitinib as a potential scintigraphic probe for the detection of tumors expressing epidermal growth factor receptors.
Topics: Animals; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; Contrast Media; ErbB Receptors; Gefitinib; Humans; Isotope Labeling; Metabolic Clearance Rate; Mice; Mice, Inbred BALB C; Molecular Probe Techniques; Molecular Probes; Quinazolines; Rabbits; Radionuclide Imaging; Reproducibility of Results; Sensitivity and Specificity; Technetium; Tissue Distribution | 2015 |
Role of epidermal growth factor receptor and endoplasmic reticulum stress in vascular remodeling induced by angiotensin II.
Topics: ADAM Proteins; ADAM17 Protein; Angiotensin II; Animals; Disease Models, Animal; Endoplasmic Reticulum Stress; Endothelium, Vascular; ErbB Receptors; Erlotinib Hydrochloride; Hypertension; Hypertrophy; Mice; Muscle, Smooth, Vascular; Phenylbutyrates; Quinazolines; Random Allocation; Role; Sensitivity and Specificity; Signal Transduction; Vascular Remodeling | 2015 |
Highly sensitive HPLC-DAD method for the assay of gefitinib in patient plasma and cerebrospinal fluid: application to a blood-brain barrier penetration study.
Topics: Blood-Brain Barrier; Brain Neoplasms; Chromatography, High Pressure Liquid; Gefitinib; Humans; Linear Models; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction | 2015 |
The therapy of gefitinib towards breast cancer partially through reversing breast cancer biomarker arginine.
Topics: Adult; Antineoplastic Agents; Area Under Curve; Arginine; Breast Neoplasms; Case-Control Studies; Female; Gefitinib; Humans; Mass Spectrometry; Metabolomics; Predictive Value of Tests; Quinazolines; ROC Curve; Sensitivity and Specificity | 2015 |
Simultaneous determination of gefitinib and its major metabolites in mouse plasma by HPLC-MS/MS and its application to a pharmacokinetics study.
Topics: Animals; Chromatography, High Pressure Liquid; Drug Stability; Female; Gefitinib; Linear Models; Mice; Mice, Nude; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2016 |
therascreen® EGFR RGQ PCR Kit: A Companion Diagnostic for Afatinib and Gefitinib in Non-Small Cell Lung Cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Reagent Kits, Diagnostic; Sensitivity and Specificity | 2016 |
Midkine Deteriorates Cardiac Remodeling via Epidermal Growth Factor Receptor Signaling in Chronic Kidney Disease.
Topics: Animals; Animals, Newborn; Cardiomegaly; Cells, Cultured; Cytokines; ErbB Receptors; Gefitinib; Mice; Mice, Inbred C57BL; Mice, Knockout; Midkine; Myocytes, Cardiac; Nephrectomy; Phosphorylation; Quinazolines; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Sensitivity and Specificity; Signal Transduction; Ventricular Remodeling | 2016 |
Discovery of new hit-molecules targeting Plasmodium falciparum through a global SAR study of the 4-substituted-2-trichloromethylquinazoline antiplasmodial scaffold.
Topics: Antimalarials; Cell Survival; Drug Discovery; Hep G2 Cells; Humans; Plasmodium falciparum; Quinazolines; Sensitivity and Specificity; Structure-Activity Relationship | 2017 |
A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Precision Medicine; Prognosis; Quinazolines; Reagent Kits, Diagnostic; Sensitivity and Specificity; Treatment Outcome | 2017 |
Quality evaluation of Evodia rutaecarpa (Juss.) Benth by high performance liquid chromatography with photodiode-array detection.
Topics: Calibration; Chromatography, High Pressure Liquid; Cluster Analysis; Drug Stability; Evodia; Indole Alkaloids; Limonins; Magnetic Resonance Spectroscopy; Medicine, Chinese Traditional; Molecular Structure; Plant Extracts; Principal Component Analysis; Quality Control; Quercetin; Quinazolines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Solvents; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet | 2008 |
A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity; Survival Rate | 2008 |
A liquid chromatography mass spectrometry assay for determination of PD168393, a specific and irreversible inhibitor of erbB membrane tyrosine kinases, in rat serum.
Topics: Animals; Chromatography, Liquid; Quinazolines; Rats; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2008 |
Highly sensitive and rapid LC-ESI-MS/MS method for the simultaneous quantification of uroselective alpha1-blocker, alfuzosin and an antimuscarinic agent, solifenacin in human plasma.
Topics: Adrenergic alpha-Antagonists; Chromatography, Liquid; Drug Stability; Humans; Male; Methyl Ethers; Muscarinic Antagonists; Propranolol; Quinazolines; Quinuclidines; Reference Standards; Sensitivity and Specificity; Solifenacin Succinate; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tetrahydroisoquinolines | 2008 |
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quality of Life; Quinazolines; Sensitivity and Specificity | 2009 |
EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Female; Gefitinib; Genes, erbB-2; Genes, ras; Genome; Humans; In Situ Hybridization, Fluorescence; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Probability; Prognosis; Quinazolines; Retrospective Studies; Sensitivity and Specificity; Statistics, Nonparametric; Survival Analysis | 2009 |
Disposable DNA biosensor with the carbon nanotubes-polyethyleneimine interface at a screen-printed carbon electrode for tests of DNA layer damage by quinazolines.
Topics: Animals; Biosensing Techniques; Carbon; Cattle; Disposable Equipment; DNA; DNA Damage; Electric Conductivity; Electric Impedance; Electrochemistry; Electrodes; Electrolytes; Nanotubes, Carbon; Polyethyleneimine; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Surface Properties; Time Factors | 2009 |
Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective.
Topics: Antineoplastic Agents; Brazil; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost Control; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Sensitivity and Specificity; Taxoids | 2008 |
Liquid chromatography/tandem mass spectrometry for the determination of changrolin in rat plasma: application to a bioavailability study.
Topics: Animals; Anti-Arrhythmia Agents; Biological Availability; Calibration; Chromatography, Liquid; Quinazolines; Rats; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2009 |
Quantitation of alfuzosin hydrochloride in pharmaceutical formulations by RP-HPLC.
Topics: Adrenergic alpha-Antagonists; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Quinazolines; Sensitivity and Specificity; Tablets | 2009 |
Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment.
Topics: Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mutation; Quinazolines; ROC Curve; Sensitivity and Specificity; Smoking | 2009 |
Effects of cigarette smoking on mucin production in human middle ear epithelial cells.
Topics: Analysis of Variance; Blotting, Western; Cells, Cultured; Ear, Middle; Epithelial Cells; ErbB Receptors; Humans; Mucins; Otitis Media; Quinazolines; Reference Values; Respiratory Mucosa; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Smoke; Smoking; Tumor Necrosis Factor-alpha; Tyrphostins; Up-Regulation | 2009 |
EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
Topics: Adolescent; Blotting, Western; Cell Proliferation; Child; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Prognosis; Quinazolines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Deletion; Tumor Cells, Cultured | 2009 |
Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry.
Topics: Antineoplastic Agents; Chromatography, Liquid; Crown Ethers; Humans; Quinazolines; Sensitivity and Specificity; Tandem Mass Spectrometry | 2009 |
Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dasatinib; Humans; Lapatinib; Limit of Detection; Mass Spectrometry; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Sensitivity and Specificity; Thiazoles | 2009 |
Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression; Gene Expression Profiling; Humans; Lapatinib; Models, Molecular; Oligonucleotide Array Sequence Analysis; Quinazolines; Sensitivity and Specificity; Signal Transduction; Urinary Bladder Neoplasms | 2009 |
Acoustic radiation force and optical spectroscopy for assessing tumor vessel normalization during anti-angiogenic therapy.
Topics: Acoustics; Angiogenesis Inhibitors; Animals; Biomarkers, Tumor; Cell Line, Tumor; Glioblastoma; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Oxygen; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Spectrum Analysis; Treatment Outcome | 2009 |
Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Disease Models, Animal; ErbB Receptors; Flow Cytometry; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Paclitaxel; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Random Allocation; Sensitivity and Specificity; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2011 |
Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.
Topics: Aged; Animals; Blotting, Western; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Fluorescent Antibody Technique; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
Topics: Adult; Aged; Antibodies, Monoclonal; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; DNA; ErbB Receptors; Exons; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Pleural Effusion, Malignant; Polymerase Chain Reaction; Quinazolines; Recurrence; Sensitivity and Specificity; Sequence Deletion | 2011 |
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Markov Chains; Medical Oncology; Middle Aged; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Sensitivity and Specificity | 2012 |
Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).
Topics: Antineoplastic Agents; Brain Neoplasms; Chemical Fractionation; Child; Chromatography, Liquid; Drug Stability; Humans; Piperidines; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2011 |
A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Case-Control Studies; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2011 |
Determination of cediranib in mouse plasma and brain tissue using high-performance liquid chromatography-mass spectrometry.
Topics: Animals; Brain Chemistry; Chromatography, High Pressure Liquid; Liquid-Liquid Extraction; Mice; Quinazolines; Regression Analysis; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2011 |
Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma.
Topics: Animals; Benzamides; Chromatography, Liquid; Glucuronides; Humans; Linear Models; Mice; Pyrimidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2012 |
Validation of a liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of Sotrastaurin and its metabolite N-desmethyl-sotrastaurin in human blood.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Humans; Least-Squares Analysis; Pyrroles; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2012 |
Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer.
Topics: Animals; Antipsychotic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Gefitinib; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Quinazolines; Random Allocation; Sensitivity and Specificity; Trifluoperazine; Tumor Cells, Cultured | 2012 |
Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue.
Topics: Calibration; Chromatography, High Pressure Liquid; Edetic Acid; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Quinazolines; Sensitivity and Specificity; Tandem Mass Spectrometry | 2012 |
Simultaneous quantitation of IC87114, roflumilast and its active metabolite roflumilast N-oxide in plasma by LC-MS/MS: application for a pharmacokinetic study.
Topics: Adenine; Aminopyridines; Animals; Benzamides; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Linear Models; Male; Quinazolines; Rats; Rats, Wistar; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2012 |
Selective, sensitive and rapid liquid chromatography-tandem mass spectrometry method for the determination of alfuzosin in human plasma.
Topics: Adrenergic alpha-Antagonists; Chromatography, Liquid; Humans; Quinazolines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2003 |
Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry.
Topics: Calibration; Chromatography, Liquid; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Humans; Mass Spectrometry; Quinazolines; Reproducibility of Results; Sensitivity and Specificity | 2003 |
In vitro interactions of licensed and novel antifungal drugs against Fusarium spp.
Topics: Amphotericin B; Antifungal Agents; Drug Interactions; Drug Resistance, Fungal; Fusarium; Humans; Itraconazole; Microbial Sensitivity Tests; Naphthalenes; Pyrimidines; Quinazolines; Sensitivity and Specificity; Terbinafine; Thiazoles; Triazoles; Voriconazole | 2004 |
Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2004 |
Measurement of the sign and the magnitude of heteronuclear coupling constants from spin-state-edited J-cross-polarization NMR experiments.
Topics: Carbon; Data Interpretation, Statistical; Magnetic Resonance Spectroscopy; Menthol; Molecular Conformation; Nuclear Magnetic Resonance, Biomolecular; Protons; Quinazolines; Sensitivity and Specificity; Spin Labels; Triazoles | 2004 |
Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection.
Topics: Chromatography, High Pressure Liquid; ErbB Receptors; Erlotinib Hydrochloride; Humans; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2005 |
High performance liquid chromatography analysis of a 4-anilinoquinazoline derivative (PD153035), a specific inhibitor of the epidermal growth factor receptor tyrosine kinase, in rat plasma.
Topics: Animals; Chromatography, High Pressure Liquid; Enzyme Inhibitors; ErbB Receptors; Male; Quinazolines; Rats; Rats, Wistar; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2005 |
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer.
Topics: Carcinoma, Medullary; Carcinoma, Papillary; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Mutation; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor Protein-Tyrosine Kinases; Sensitivity and Specificity; Thyroid Neoplasms; Treatment Outcome | 2004 |
Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry.
Topics: Animals; Biliary Tract Neoplasms; Chromatography, High Pressure Liquid; Drug Stability; ErbB Receptors; Female; Gefitinib; Humans; Liver; Mass Spectrometry; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Skin | 2005 |
Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues.
Topics: Acetates; Animals; Antineoplastic Agents; Calibration; Chemistry, Pharmaceutical; Chromatography; Chromatography, Liquid; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; Ions; Liver; Mass Spectrometry; Mice; Mice, Inbred BALB C; Models, Chemical; Neoplasms; Pentanes; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Time Factors; Tissue Distribution; Trazodone | 2005 |
High-performance liquid chromatography-mass spectrometry method for determination of anagrelide in human plasma.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Fibrinolytic Agents; Humans; Mass Spectrometry; Quinazolines; Reproducibility of Results; Sensitivity and Specificity | 2005 |
Sensitive and specific quantification of the anticancer agent ZD1839 (Gefitinib) in plasma by on-column focusing capillary liquid chromatography-tandem mass spectrometry.
Topics: Antineoplastic Agents; Chromatography, Liquid; Gefitinib; Humans; Mass Spectrometry; Quinazolines; Reproducibility of Results; Sensitivity and Specificity | 2005 |
Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Gefitinib; Gene Amplification; Genes, erbB-1; Genetic Heterogeneity; Humans; Lung Neoplasms; Mutation; Peptide Nucleic Acids; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity | 2005 |
Antiangiogenic effect of ZD1839 against murine renal cell carcinoma (RENCA) in an orthotopic mouse model.
Topics: Animals; Biopsy, Needle; Blotting, Western; Carcinoma, Renal Cell; Cell Proliferation; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Quinazolines; Sensitivity and Specificity; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Sensitivity and Specificity; Sex Characteristics | 2005 |
Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity; Stomach Neoplasms | 2005 |
A specific and sensitive assay for gefitinib using the enzyme-linked immunosorbent assay in human serum.
Topics: Animals; Blood; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Humans; Quinazolines; Rabbits; Sensitivity and Specificity | 2005 |
Gefitinib is effective against juvenile pilocytic astrocytoma in vitro.
Topics: Astrocytoma; Cell Proliferation; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Profiling; Humans; Immunohistochemistry; Oligonucleotide Array Sequence Analysis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Thymidine; Tumor Cells, Cultured | 2006 |
Drug discovery: playing dirty.
Topics: Animals; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Clozapine; Depression; Drug Approval; Drug Design; Drug Evaluation, Preclinical; Drug Industry; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Sensitivity and Specificity; Substrate Specificity; Therapeutics; United States; United States Food and Drug Administration | 2005 |
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatography, High Pressure Liquid; Deoxyribonuclease I; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Exons; Female; Formaldehyde; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Paraffin Embedding; Predictive Value of Tests; Quinazolines; Sensitivity and Specificity | 2006 |
HER2 expression as a potential marker for response to therapy targeted to the EGFR.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Laser Scanning Cytometry; Mitogen-Activated Protein Kinases; Phosphorylation; Predictive Value of Tests; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Sensitivity and Specificity; Structure-Activity Relationship; Trastuzumab; Tyrphostins | 2006 |
Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Gene Expression Profiling; Head and Neck Neoplasms; Humans; Male; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Analysis, DNA; Signal Transduction; Structure-Activity Relationship; Time Factors | 2006 |
A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer.
Topics: Biopsy; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Models, Biological; Point Mutation; Predictive Value of Tests; Quinazolines; Sensitivity and Specificity; Treatment Failure | 2006 |
Serum tumor markers for pancreatic cancer: the dawn of new era?
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; DNA Methylation; DNA, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proteomics; Quinazolines; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2006 |
Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Organophosphorus Compounds; Quinazolines; Sensitivity and Specificity; Treatment Outcome; Xenograft Model Antitumor Assays | 2006 |
Quantitative analyses of indoloquinazoline alkaloids in Fructus Evodiae by high-performance liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Drugs, Chinese Herbal; Evodia; Fruit; Indoles; Plant Extracts; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2006 |
Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorodeoxyglucose F18; Gefitinib; Glucose; Humans; Lung Neoplasms; Mice; Mice, SCID; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Sensitivity and Specificity; Treatment Outcome; Tumor Cells, Cultured | 2006 |
EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Polymerase Chain Reaction; Prognosis; Quinazolines; Sensitivity and Specificity; Treatment Outcome | 2006 |
Detection of epidermal growth factor receptor variations by partially denaturing HPLC.
Topics: Antineoplastic Agents; Biopsy; Chromatography, High Pressure Liquid; Codon; ErbB Receptors; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity | 2007 |
Validated HPLC and HPTLC stability-indicating methods for determination of alfuzosin hydrochloride in bulk powder and pharmaceutical formulations.
Topics: Adrenergic alpha-Antagonists; Calibration; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Pharmaceutical Preparations; Quinazolines; Reference Standards; Sensitivity and Specificity | 2006 |
Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Sensitivity and Specificity; Urinary Bladder Neoplasms | 2007 |
The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor, ErbB-2; Sensitivity and Specificity; Transfection; Tumor Cells, Cultured | 2007 |
The LeFE algorithm: embracing the complexity of gene expression in the interpretation of microarray data.
Topics: Algorithms; Breast Neoplasms; Cell Line, Tumor; Cluster Analysis; Computational Biology; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotide Array Sequence Analysis; Pattern Recognition, Automated; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Smoking | 2007 |
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity | 2007 |
Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.
Topics: Adenocarcinoma; Animals; Apoptosis; bcl-Associated Death Protein; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Humans; Lung Neoplasms; Mice; Mutation; Quinazolines; Sensitivity and Specificity | 2007 |
Potentiometric sensors enabling fast screening of the benign prostatic hyperplasia drug alfuzosin in pharmaceuticals, urine and serum.
Topics: Drug Evaluation, Preclinical; Electrochemistry; Electrodes; Humans; Hydrogen-Ion Concentration; Male; Molecular Structure; Pharmaceutical Preparations; Potentiometry; Prostatic Hyperplasia; Quinazolines; Reference Values; Sensitivity and Specificity | 2007 |
Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation.
Topics: Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Sequence Data; Oligonucleotides; Peptide Nucleic Acids; Point Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity | 2008 |
Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Dinoprostone; Enzyme Activation; Humans; Intracellular Fluid; Isoenzymes; Kinetics; Magnesium; Monocytes; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Phosphorylation; Precipitin Tests; Pyridazines; Quinazolines; Recombinant Proteins; Sensitivity and Specificity; Tumor Cells, Cultured | 1995 |
Quantification of 2,3-dihydro-7-methoxypyrrolo-[2,1-b]-quinazolin-9(1H)-one, a new antiallergic agent, by high-performance liquid chromatography in serum.
Topics: Animals; Chromatography, High Pressure Liquid; Hypersensitivity; Quinazolines; Rats; Reproducibility of Results; Sensitivity and Specificity | 1994 |
Determination of a novel and potent cyclic GMP phosphodiesterase inhibitor, 4-([3,4-(methylenedioxy)-benzyl]amino)-6,7,8-trimethoxyquinazoline, in dog plasma by high-performance liquid chromatography.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Chromatography, High Pressure Liquid; Dogs; Quality Control; Quinazolines; Regression Analysis; Sensitivity and Specificity | 1994 |
Fluorometric determination of cyanate in plasma by conversion to 2,4(1H,3H)-quinazolinedione and separation by high-performance liquid chromatography.
Topics: Adult; Artifacts; Chromatography, High Pressure Liquid; Cyanates; Female; Fluorometry; Humans; Male; Middle Aged; Quinazolines; Reference Values; Reproducibility of Results; Sensitivity and Specificity; Smoking; Urea | 1993 |
Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BPH Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Anxiety; Case-Control Studies; Cohort Studies; Cross-Sectional Studies; Humans; Longitudinal Studies; Male; Middle Aged; Perception; Prostatic Hyperplasia; Psychometrics; Quality of Life; Quinazolines; Sensitivity and Specificity; Sexual Behavior; Surveys and Questionnaires; Urination Disorders | 1997 |
Pharmacokinetics and biologic activity of the novel mast cell inhibitor, 4-(3-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in mice.
Topics: Animals; Chromatography, High Pressure Liquid; Female; Immunoglobulin E; Mast Cells; Mice; Mice, Inbred Strains; Quinazolines; Rats; Reproducibility of Results; Sensitivity and Specificity | 1999 |
Quantitative high-performance liquid chromatographic method for pharmacokinetic studies of the potent mast cell inhibitor 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P131).
Topics: Animals; Anti-Allergic Agents; Area Under Curve; Cell Line; Chromatography, High Pressure Liquid; Half-Life; Mast Cells; Mice; Mice, Inbred BALB C; Pilot Projects; Quinazolines; Rats; Reproducibility of Results; Sensitivity and Specificity | 1999 |
A high-resolution, fluorescence-based method for localization of endogenous alkaline phosphatase activity.
Topics: Alkaline Phosphatase; Animals; Female; Fluorescent Dyes; Immunohistochemistry; Intestines; Kidney; Kinetics; Microscopy, Fluorescence; Organophosphorus Compounds; Osteosarcoma; Ovary; Quinazolines; Quinazolinones; Rats; Sensitivity and Specificity; Tumor Cells, Cultured; Zebrafish | 1999 |
The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex) in a nonhuman primate model.
Topics: Animals; Antimetabolites, Antineoplastic; Half-Life; Infusions, Intravenous; Macaca mulatta; Male; Metabolic Clearance Rate; Models, Biological; Quinazolines; Sensitivity and Specificity; Thiophenes; Thymidylate Synthase | 1999 |
Modified high-performance liquid chromatography assay for the measurement of 2'-deoxyuridine in human plasma and its application to pharmacodynamic studies of antimetabolite drugs.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Deoxyuridine; Folic Acid Antagonists; Humans; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2000 |
Expression in yeast and purification of functional recombinant human poly(ADP-ribose)polymerase (PARP). Comparative pharmacological profile with that of the rat enzyme.
Topics: 1-Naphthylamine; Animals; Benzamides; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Gene Expression; Humans; Kinetics; Male; Naphthalimides; Phenanthrenes; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolines; Quinolones; Rats; Recombinant Proteins; Saccharomyces; Sensitivity and Specificity; Testis | 2000 |
High-performance liquid chromatographic analysis of the tyrphostin AG1478, a specific inhibitor of the epidermal growth factor receptor tyrosine kinase, in mouse plasma.
Topics: Animals; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Enzyme Stability; ErbB Receptors; Freezing; Mice; Quinazolines; Reference Standards; Sensitivity and Specificity; Tyrphostins | 2001 |
The impact of p53 status on cellular sensitivity to antifolate drugs.
Topics: Apoptosis; Blotting, Western; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Mutational Analysis; DNA, Neoplasm; Dose-Response Relationship, Drug; Folic Acid Antagonists; Gene Expression Regulation, Neoplastic; Genotype; Glutamates; Guanine; Humans; Methotrexate; Mutation; Pemetrexed; Quinazolines; Sensitivity and Specificity; Tetrahydrofolates; Thiophenes; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Gefitinib; Humans; KB Cells; Quinazolines; Sensitivity and Specificity; Tumor Cells, Cultured | 2001 |